153 related articles for article (PubMed ID: 35276437)
1. A survey of use of mTOR inhibitors in patients with lymphangioleiomyomatosis listed for lung transplant.
Warrior K; Leard LE; Nair AR; Gries CJ; Fisher AJ; Johnson SR; McCormack FX; Dilling DF
Respir Med; 2022; 195():106779. PubMed ID: 35276437
[TBL] [Abstract][Full Text] [Related]
2. Should mammalian target of rapamycin inhibitors be stopped in women with lymphangioleiomyomatosis awaiting lung transplantation?
El-Chemaly S; Goldberg HJ; Glanville AR
Expert Rev Respir Med; 2014 Dec; 8(6):657-60. PubMed ID: 25199529
[TBL] [Abstract][Full Text] [Related]
3. Experience of Lung Transplantation in Patients with Lymphangioleiomyomatosis at a Brazilian Reference Centre.
Baldi BG; Samano MN; Campos SV; de Oliveira MR; Junior JEA; Carraro RM; Teixeira RHOB; Minguini IP; Burlina R; Pato EZS; Carvalho CRR; Costa AN
Lung; 2017 Dec; 195(6):699-705. PubMed ID: 28823029
[TBL] [Abstract][Full Text] [Related]
4. Lung transplantation for lymphangioleiomyomatosis.
Warrior K; Dilling DF
J Heart Lung Transplant; 2023 Jan; 42(1):40-52. PubMed ID: 36334961
[TBL] [Abstract][Full Text] [Related]
5. Mayo clinic experience of lung transplantation in pulmonary lymphangioleiomyomatosis.
Ussavarungsi K; Hu X; Scott JP; Erasmus DB; Mallea JM; Alvarez F; Lee AS; Keller CA; Ryu JH; Burger CD
Respir Med; 2015 Oct; 109(10):1354-9. PubMed ID: 26321137
[TBL] [Abstract][Full Text] [Related]
6. Long-term clinical course and progression of lymphangioleiomyomatosis in a single lung transplant referral centre in Korea.
Chang S; Choi JS; Leem AY; Lee SH; Lee SH; Kim SY; Chung KS; Jung JY; Kang YA; Kim YS; Lee JG; Paik HC; Shim HS; Lee EH; Park MS
Sci Rep; 2022 May; 12(1):8260. PubMed ID: 35585116
[TBL] [Abstract][Full Text] [Related]
7. Lung Transplantation for Lymphangioleiomyomatosis in Japan.
Ando K; Okada Y; Akiba M; Kondo T; Kawamura T; Okumura M; Chen F; Date H; Shiraishi T; Iwasaki A; Yamasaki N; Nagayasu T; Chida M; Inoue Y; Hirai T; Seyama K; Mishima M;
PLoS One; 2016; 11(1):e0146749. PubMed ID: 26771878
[TBL] [Abstract][Full Text] [Related]
8. Favorable survival even with high disease-specific complication rates in lymphangioleiomyomatosis after lung transplantation-long-term follow-up of a Japanese center.
Kurosaki T; Otani S; Miyoshi K; Okazaki M; Sugimoto S; Suno M; Yamane M; Kobayashi M; Oto T; Toyooka S
Clin Respir J; 2020 Feb; 14(2):116-123. PubMed ID: 31729820
[TBL] [Abstract][Full Text] [Related]
9. mTOR treatment in lymphangioleiomyomatosis: the role of everolimus.
Yates DH
Expert Rev Respir Med; 2016; 10(3):249-60. PubMed ID: 26847859
[TBL] [Abstract][Full Text] [Related]
10. Lymphangioleiomyomatosis treatment with sirolimus.
Casanova A; María Girón R; Acosta O; Barrón M; Valenzuela C; Ancochea J
Arch Bronconeumol; 2011 Sep; 47(9):470-2. PubMed ID: 21440356
[TBL] [Abstract][Full Text] [Related]
11. Lung transplantation in the management of patients with lymphangioleiomyomatosis: baseline data from the NHLBI LAM Registry.
Maurer JR; Ryu J; Beck G; Moss J; Lee JC; Finlay G; Brown K; Chapman J; McMahan J; Olson E; Ruoss S; Sherer S;
J Heart Lung Transplant; 2007 Dec; 26(12):1293-9. PubMed ID: 18096481
[TBL] [Abstract][Full Text] [Related]
12. Sirolimus Suppresses Phosphorylation of Cofilin and Reduces Interstitial Septal Thickness in Sporadic Lymphangioleiomyomatosis.
Huang YL; Chen PR; Lai YJ; Hsu HH
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445268
[TBL] [Abstract][Full Text] [Related]
13. Lymphangioleiomyomatosis.
Doubková M; Štefániková M; Čan V; Merta Z; Svoboda M
Klin Onkol; 2019; 32(5):367-374. PubMed ID: 31610670
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of sirolimus in lymphangioleiomyomatosis.
McCormack FX; Inoue Y; Moss J; Singer LG; Strange C; Nakata K; Barker AF; Chapman JT; Brantly ML; Stocks JM; Brown KK; Lynch JP; Goldberg HJ; Young LR; Kinder BW; Downey GP; Sullivan EJ; Colby TV; McKay RT; Cohen MM; Korbee L; Taveira-DaSilva AM; Lee HS; Krischer JP; Trapnell BC; ;
N Engl J Med; 2011 Apr; 364(17):1595-606. PubMed ID: 21410393
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes and survival following lung transplantation in patients with lymphangioleiomyomatosis.
Khawar MU; Yazdani D; Zhu Z; Jandarov R; Dilling DF; Gupta N
J Heart Lung Transplant; 2019 Sep; 38(9):949-955. PubMed ID: 31303421
[TBL] [Abstract][Full Text] [Related]
16. Single lung transplantation for lymphangioleiomyomatosis: a single-center experience in Japan.
Oishi H; Watanabe T; Matsuda Y; Noda M; Ejima Y; Saiki Y; Seyama K; Kondo T; Okada Y
Surg Today; 2018 Oct; 48(10):944-950. PubMed ID: 29808303
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and adverse events of mTOR inhibitors in lymphangioleiomyomatosis: systematic review and meta-analysis.
Gao N; Zhang T; Ji J; Xu KF; Tian X
Orphanet J Rare Dis; 2018 Aug; 13(1):134. PubMed ID: 30107845
[TBL] [Abstract][Full Text] [Related]
18. Canadian respirologists' experience with lymphangioleiomyomatosis.
Pollock-BarZiv SM; Cohen MM; Maclean H; Downey GP
Can Respir J; 2002; 9(6):413-6. PubMed ID: 12522487
[TBL] [Abstract][Full Text] [Related]
19. [Lymphangioleiomyomatosis].
Wirtz H
Zentralbl Chir; 2013 Oct; 138 Suppl 1():S59-74; quiz 75-6. PubMed ID: 24277558
[TBL] [Abstract][Full Text] [Related]
20. Effect of beta-agonists on LAM progression and treatment.
Le K; Steagall WK; Stylianou M; Pacheco-Rodriguez G; Darling TN; Vaughan M; Moss J
Proc Natl Acad Sci U S A; 2018 Jan; 115(5):E944-E953. PubMed ID: 29339522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
